Harmony Biosciences Holdings, Inc. Completes Sale of 8,000,000 Shares in Registered Public Offering

On November 1, 2024, Harmony Biosciences Holdings, Inc. announced in a filing with the Securities and Exchange Commission (SEC) that certain shareholders, known as the “Selling Shareholders,” had successfully sold 8,000,000 shares of the company’s common stock. The shares were priced at $0.00001 per share and were offered in a registered public offering under the Company’s Registration Statement on Form S-3 ASR (File No. 333-260905). The registration statement had become automatically effective upon filing on November 9, 2021.

The shares were sold in line with an Underwriting Agreement dated October 30, 2024, which involved Harmony Biosciences Holdings, the Selling Shareholders, and J.P. Morgan Securities LLC as the Underwriter. Additionally, as part of the agreement, the Selling Shareholders granted the Underwriter a 30-day option to purchase up to an additional 1,200,000 shares of Common Stock on the same terms.

It’s important to note that all proceeds from this offering will go to the Selling Shareholders, with Harmony Biosciences Holdings not receiving any of the proceeds from the sale. The details of the Underwriting Agreement were further outlined in the filing, referring to specific terms and conditions governing the sale.

The filing also included a mention of the full text of the Underwriting Agreement, provided as Exhibit 1.1, and an opinion from Latham & Watkins LLP regarding the validity of the shares and the option shares. This opinion was filed as Exhibit 5.1 and incorporated into the submission.

In terms of financial reports and exhibits, the filing listed the necessary documentation including the Underwriting Agreement, Latham & Watkins LLP’s opinion, a consent of Latham & Watkins LLP, and a cover page interactive data file embedded within the Inline XBRL document.

Harmony Biosciences Holdings, Inc. currently trades on The Nasdaq Global Market under the trading symbol “HRMY.” The company operates from its principal executive offices located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462.

The information provided in this SEC filing sheds light on the recent financial activities conducted by Harmony Biosciences Holdings, Inc., exemplifying the strategic moves made by the company and certain shareholders in the realm of public offerings and stock transactions.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Harmony Biosciences’s 8K filing here.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.